doi: 10.1161/hq0302.105593
© 2002 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice
From the Departments of Cardiovascular and Metabolic Disease (R.J.A., P.-A.B., S.L., W.W., A.F.) and Inflammation (H.J.S.), Pfizer Global Research and Development, Groton, Conn.
Address correspondence to Dr. Robert J. Aiello, Pfizer Inc, PGRD, Eastern Point Rd, Groton, CT 06340. E-mail robert_j_aiello{at}groton.pfizer.com
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Leukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr-/-) mice and apolipoprotein E deficient (apoE-/-) mice were treated with a specific LTB4 receptor antagonist, CP-105,696, for 35 days. In apoE-/-mice, treatment with the LTB4 antagonist did not affect plasma lipid concentrations but significantly reduced CD11b levels both in vascular lesions and whole blood. Compared with age-matched controls, lipid accumulation and monocyte infiltration were significantly reduced in treated apoE-/- mice at all time points tested. Lesion area reduction was also demonstrated in LDLr-/- mice maintained on a high-fat diet. LTB4 antagonism had no significant effect on lesion size in mice possessing the null alleles for another chemotactic agent, monocyte chemoattractant protein-1 (MCP-1-/-xapoE-/-), suggesting MCP-1 and LTB4 may either interact or exert their effects by a common mechanism. These results demonstrate that in a preclinical model of atherosclerosis LTB4 receptor blockade reduces lesion progression and further suggest a previously unrecognized role for LTB4 or other oxidized lipids recognized by the BLTR receptor in the pathogenesis of this disease.
Key Words: leukotriene B4 • atherosclerosis • monocyte chemoattractant protein-1
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The pathogenesis of atherosclerosis is a complex process, which involves the recruitment and activation of monocytes in the developing atherosclerotic lesion.1 It is thought to initiate when circulating monocytes are first attracted to a site of vascular injury through the upregulation of adhesion molecules and chemotactic factors in the lesion.2,3 Once attached to the vessel wall, monocytes, attracted by a gradient of chemotactic factors, migrate between the endothelial cells into the subendothelial space where they differentiate into macrophages and become lipid-laden foam cells.2 A growing body of evidence suggests that the recruitment of monocytes is governed by cell-specific chemoattractants. Several molecules have chemotactic activity for monocytes, including N-formylmethionyl peptides exemplified by N-formylmethionyl-leucyl-phenylalanine (FMLP), the complement fragment C5a, the arachidonic acid metabolite leukotriene B4 (LTB4), 12-hydroxyeicosatetraenoic acid (12-HETE), and the chemoattractant monocyte chemotactic protein-1 (MCP-1).4
See page 361 and cover
MCP-1 is the prototype of the CC chemokine ß subfamily and exhibits the most potent chemotactic activity for monocytes.5 MCP-1 is highly expressed in human atheromatous plaques,6 and its overexpression contributes to the development of atherosclerosis in mouse models.7 In hypercholesterolemic mice, a deficiency in either MCP-18 or the MCP-1 receptor (CCR2)9 results in a marked decrease in atheromas and fewer monocytes in vascular lesions. However, at later stages of lesion development in these mice, differences in lesion size relative to wild type become less pronounced. These data suggest that other chemotactic factors are likely compensating for the lack of MCP-1.
LTB4, a product of the 5-lipoxygenase pathway of arachidonic acid metabolism, is also a potent chemoattractant and proinflammatory mediator thought to be involved in the pathogenesis of several inflammatory diseases.10,11 Ex vivo, human vascular plaques have been shown to produce leukotrienes,12 but the evidence for a specific role of 5-lipoxygenase in atherosclerosis is only circumstantial. However, most cell types, including macrophages found in lesions, are capable of nonenzymatically producing isomers of LTB4, such as isoleukotrienes, by free radical oxidation.13 These oxygenated products of arachidonic acid are known to modulate diverse biological processes including leukocyte recruitment and activation.
LTB4 and B4 isoleukotrienes induce their effects by binding to the high-affinity LTB4 receptor (BLTR)14 which is expressed on inflammatory cells such as neutrophils, eosinophils, and macrophages. Moreover, LTB4 receptor antagonists have been shown to inhibit the recruitment of macrophages, neutrophils, and eosinophils in preclinical disease models such as experimental autoimmune encephalomyelditis, collagen-induced arthritis, and allograft transplantation.15–17 Thus, LTB4 or other ligands that bind to the LTB4 receptor may play a proatherogenic role because of its ability to promote the adhesion and chemotaxis of leukocytes across the endothelium. To explore the potential pathophysiological role of LTB4 in atherosclerosis, we tested a potent specific LTB4 receptor antagonist, CP-105,696 on lesion progression in several murine models of atherosclerosis. CP-105,696 was chosen because it was previously shown to inhibit 3H-LTB4 binding to murine receptors18 with nanomolar potency and to selectively block LTB4-mediated functional responses of murine leukocytes in vitro and in vivo.16,17
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mouse line derivation
All animal experiments were performed according to protocols approved by the institutional committee for use and care of laboratory animals. Genetically modified apolipoprotein E-deficient (ApoE-/-), LDL receptor-deficient (LDLr-/-), and MCP-1-deficient (MCP-1-/-) mice used in the present study have been previously described and characterized.19,20 To obtain mice homozygous for both the apoE and MCP-1 (ScyA2) null alleles, male apoE-/- mice on a C57B/6 background (C57E-/-) were mated with heterozygous female MCP-1-/+ mice on a C57B/6 background. The resulting apoE-/-xMCP-1-/+ progeny were identified by Southern blot analysis and inbred to produce apoE-/-xMCP-1-/- (C57E-/-xMCP-1 -/-) and control apoE-/-xMCP-1+/+ (C57E-/-) mice. ApoE-/- mice on the mixed genetic background 1290laxC57B/6 (129E-/-) were bred in-house and derived from brother and sister matings. All mice were weaned at 21 days, maintained on a 1-hour light/dark cycle, and fed either a chow or a Western-type diet.21
Administration of Compound
CP-105,696 was evaluated for its effects on lesion development in age-matched groups of mice (15 to 30 weeks old at time of sacrifice) with a 35-day treatment protocol. Subgroups of mice were treated with CP-105,696 for shorter times (7 to 14 days) for evaluation of acute changes in tissue gene expression as noted in the table and figure legends. In all study groups, the compound was administered by oral gavage once daily in a vehicle composed of 0.6% Tween 80+0.25% methylcellulose in PBS. Mice received either vehicle alone, 30, 50, or 100 mg · kg-1 · d-1 of CP-105,696. No adverse effects of CP-105,696 in mice or other species have been reported.15–18
CD11b Flow Cytometric Analysis
After the treatment period, mice were anesthetized with ketamine:xylazine:PBS (1:1:2), and a whole-blood sample was collected from the abdominal aorta into Vacutainers (Becton Dickinson) containing 7.5% EDTA. Mice were then euthanized by exsanguination under anesthesia. Determination of blood monocyte CD11b expression was performed as described previously.17 Cells were pelleted by gentle centrifugation (1200 rpm, 2 minutes) and incubated with 50 µg/mL of fluorescein-conjugated rat anti-mouse CD11b IgG (Pharmingen) at room temperature for 30 minutes. To control for nonspecific binding, duplicate samples were incubated with 50 µg/mL of fluorescein-conjugated rat IgG. After 30 minutes of incubation, cells were washed with 1 mL 2% heat inactivated fetal calf serum + 0.025% sodium azide in PBS (HiFAZ) buffer and pelleted, and red blood cells were lysed with a lysing buffer (Becton Dickinson) for 10 minutes at room temperature. The cells were then washed twice and resuspended in HiFAZ buffer, and the degree of fluorescence was determined by flow cytometry. Data were collected in the list mode, and macrophage gates were defined by the forward scatter versus 90° scatter dot blots. The amount of fluorescence was expressed as a percentage of the cells counted in the macrophage gate.
Plasma Lipoproteins and Lipids
Separation of plasma lipoproteins with fast protein liquid chromatography (Pharmacia LKB Biotechnology, Inc) was performed as previously described.21 Total plasma cholesterol and triglycerides were measured by using colorimetric methods with commercially available Cholesterol/HP (Boehringer-Mannheim) and Triglycerides G (Wako Chemical) kits.
Aortic Tree Analysis
In some experiments, mice were anesthetized as above and perfusion-fixed with 4% paraformaldehyde, and the entire aortic tree was removed including the brachiocephalic region and the carotid, subclavian, and femoral branches. The tissue was cleaned of adventitia and laid out on a piece of polystyrene, and a digital image was obtained with a digital camera (Sony) attached to a copy stand. The carotid and subclavian branches were removed, and the brachiocephalic region was isolated for further processing. The percent of the aortic surface covered by lesions in the remaining portion of the aortic tree was determined by using an en face preparation as previously described.21 Each aorta was evaluated for lesion area by direct-image capture and displayed on a Trinitron monitor (Sony). The lesion area was determined in unstained tissue with ImagePro 3.1 image analysis (Image Processing Solutions). Areas of atherosclerotic plaques in aortas cleaned of adventitia appear as yellowish-white opaque areas compared with translucent non-lesioned areas. This area was quantified by manually setting thresholds for shades of black (background), gray (normal tissue), and white (lesion area).
Lesion Analysis
To determine cross-sectional lesion area, hearts were perfusion-fixed in 4% paraformaldehyde, infiltrated with 30% gum sucrose for 24 hours at 4°C, embedded in Tissue-Tek OCT compound (Sakura Finetek) and sectioned in 10 µm, -18°C, as previously described.21 The sections were stained with Oil red O (Polyscientific) and counterstained with Gill III hematoxylin (Sigma). Oil red O-stained sections of the aortic sinus and valve regions were captured directly from a digital camera attached to a Leitz Laborlux S (Leica) light microscope and displayed on a Trinitron monitor. The aortic sinus begins with the first appearance of the valve cusps delineating the lumen into 3 distinct areas. At the end of the aortic sinus, the coronaries branch off, the valve cusps no longer divide the lumen, and the perimeter of the aorta is round rather than bulging. The aortic valve begins at this point and continues to the junction of the aorta, approximately 300 µm. Image analysis was performed with ImagePro 3.1 software as described previously.21 Results are expressed as the average lesion size per section or as the percent of the total cross-sectional vessel wall stained with Oil red O. For each animal, the average lesion area of 12 to 16 sections was determined, and data are expressed as lesion size or mean percent lesion area ±SD.
Immunohistochemical Staining of Macrophages
Serial paraformaldehyde-fixed, OCT-embedded sections of aortic valves were immunostained for macrophages by using rat monoclonal antibodies (IgG2b) against MOMA-2 (BioSource) and CD11b (Pharmingen). Endogenous biotin and peroxidase activity were blocked by incubating each section with an avidin/biotin solution (Vector Laboratories) and 0.3% H2O2 in 1% bovine serum, respectively. Rat anti-mouse MOMA-2 was applied at a concentration of 25 µg/mL, and rat anti-mouse CD11b was applied at a concentration of 5 µg/mL. Incubation with primary antibodies was followed by a biotinylated donkey anti-rat IgG secondary antibody (1.4 µg/mL, Jackson ImmunoResearch), and incubation with horseradish peroxidase-conjugated streptavidin (1:500). A nonspecific rat IgG2b antibody (Pharmingen) was used as a negative control. Antibody binding was visualized with 3,3'-diaminobenzidine (Vector Laboratories), and all sections were counterstained with Gill III hematoxylin. Results are expressed as the percent of the total cross-sectional vessel wall area (normal+diseased area/section, excluding the lumen) stained with diaminobenzidine.
Peritoneal Macrophage Chemotaxis Assay
On the termination of the study, a subset of mice from each group was injected intraperitoneally with 1 mL of sterile 6% casein. After four days, peritoneal exudate cells were harvested by washing the peritoneal cavity with Hanks’ Balanced Salt Solutions (Life Technologies), supplemented with 1% fetal bovine serum. Peritoneal cells then were washed three times in RPMI-1640 supplemented with 0.1% bovine serum albumin. For chemotaxis, cells were suspended at a concentration of 2x106 cell/mL in chemotaxis buffer (RPMI-1640 supplemented with 0.1% bovine serum albumin and 20 mmol/L HEPES, pH 7.4). The cell suspension was loaded in the upper chamber of a 48-well microtaxis chamber. Murine MCP-1 or LTB4 (10 nmol/L) was added to the lower chamber, which was separated from the upper chamber by a 5-µm polycarbonate membrane. The peritoneal macrophages attached to the underside of the membrane were fixed and stained using the Diff-Quick stain set (Dade Behring Inc). The results were expressed as the mean number of cells that migrated in four high power fields (x20) in three replicate samples.
Statistics
Statistical significance was determined with unpaired Student’s t test by using the StatView statistical program (Abacus Concepts, Inc). Results are reported as mean±SD.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Analysis of Lesions
The contribution of BLTR antagonism to atherosclerosis at different stages of lesion development was studied in genetically modified murine models of atherosclerosis. Because inflammatory responses to leukotrienes have been previously shown to differ among mouse strains with different genetic backgrounds,22 two strains of apoE-/- mice on a C57B/6 background (C57E-/-) and apoE-/- mice on a mixed background of 1290la/BalbC (129E-/-), and LDLr-/- mice on a C57B/6 background were treated with a LTB4 antagonist (CP-105,696). The two different strains of apoE-/- (C57E-/- and 129E-/-) mice had similar lesion development (Table 1), and the extent of their atherosclerotic lesions increased significantly with age. The spontaneous lesions that developed in the aortic root (Figure 1) of the chow-fed apoE-/- were significantly (P<0.05) reduced in both strains of apoE-/- mice after treatment with the LTB4 antagonist CP-105,696 (Table 1). Lesions were also reduced throughout the entire aortic tree (Figure 2C and 2D). Representative sections from the brachiocephalic region of 20-week-old C57E-/- mice treated with 100 mg · kg-1 · d-1 of CP-105,696 for 35 days are shown in Figure 2A and 2B. In all groups, lesions at various stages of development could be observed in a single animal. These vascular lesions had a variety of histological appearances from multilayered foam cell deposits to advanced plaques. In general, the lesions in the C57E-/- mice treated with the LTB4 antagonist were both thinner and much less extensive than those in control C57E-/- mice. Although the LTB4 antagonist significantly reduced lesion size at all stages of lesion development, the effect of CP-105,696 was more pronounced in younger animals with smaller, less complex lesions.
|
|
|
Immunohistochemistry
We sought to determine if the decrease in lesion size was caused by a reduction in macrophage accumulation in the vessel wall. Serial sections (10 µmol/L) from control and treated mice were stained with the monoclonal rat anti-mouse antibodies to the monocyte-macrophage markers MOMA-2 and CD11b. Although the lesions were composed of a mixture of cells, immunohistochemical analysis showed a significant decrease in the number of cells immunostaining positive for MOMA-2. In general, MOMA-2 and lipid staining were reduced in lesions that were decreased in size as a consequence of treatment with CP-105,696 (Figure 1). In addition to decreased MOMA-2 staining, lesions from treated animals stained less intensely for the macrophage marker CD11b, the alpha subunit of the ß2 integrin heterodimer CD11b/CD18. In both LDLr-/- and 129E-/- mice, the decrease in lesion size after treatment with the LTB4 antagonist was associated with a decrease in CD11b staining (Table 2). This decrease in CD11b staining could result from a direct effect on CD11b expression or from a decrease in monocyte number in the smaller lesions after LTB4 antagonism.
|
CD11b expression
Previous studies have shown that CP-105,696 inhibits the LTB4-mediated upregulation of CD11b on neutrophils and monocytes in vitro. To determine whether CP-105,696 was specifically affecting monocyte function, we studied the effects of CP-105,696 on monocyte CD11b cell surface expression in vivo. As shown in Figure 3, the levels of CD11b expression in circulating monocytes were decreased in a dose-dependent manner after treatment with CP-105,696 compared with vehicle-treated controls. The decrease in the percentage of cells staining for CD11b suggest that the amount of CD11b/cell was decreased. In contrast, neither the percent total monocytes or the number of monocytes in whole blood determined as peroxidase-positive stained cells by flow cytometric analysis was affected by treatment. Together these data suggest that the LTB4 antagonist decreased the level of CD11b expressed at the plasma membrane on circulating monocytes.
|
Plasma Lipids
The administration of CP-105,696 had no significant effect on plasma lipids or body weight (Table 1) in the chow fed apoE-deficient strains of mice. However, the plasma cholesterol levels in the 129E-/- mice fed a standard chow diet ranged between 600 and 800 mg/dL, which was significantly higher than levels found in the C57E-/- strain maintained on a chow diet (300 to 500 mg/dL). Plasma triglycerides were unchanged with treatment and averaged 
150 mg/dL for all genotypes. LDLr-/- mice made hypercholesterolemic by being fed a Western diet exhibited plasma cholesterol levels ranging between 800 and 1200 mg/dL. These markedly elevated lipid levels were reduced as was body weight in LDLr-/- mice treated with CP-105,696 compared with control mice. A specific mechanism contributing to this effect on body weight and plasma lipids is unclear. No adverse effects or reduction in feed intake has been previously reported in animals studies after administration of CP-105,696. It is important to note that no effect was observed in any of the other strains of mice fed the chow diet. Size separation of plasma lipoproteins with fast protein liquid chromatography demonstrated there was a nonsignificant increase in VLDL cholesterol in mice treated with CP-105696, but otherwise the lipoprotein profiles for treated and control mice were identical (data not shown).
MCP-1 Null Allele
MCP-1 deficient mice were bred onto the C57E-/- background to determine the relative contribution of LTB4 antagonism and MCP-1 depletion on lesion formation. Consistent with previous findings8 at 16 weeks of age, mice homozygous for the MCP-1 null allele on a C57E-/- background (C57E-/-xMCP-1-/-) showed a significant but highly variable 50% reduction in lesion area in the aortic valve and sinus (Table 3) compared with C57E-/- (Table 1). As previously reported,8 these apparent differences in lesion size resulting from MCP-1 depletion were not maintained as lesion size and complexity increased with age. Although there was a significant reduction in lesions observed in the apoE-/- strains treated with CP-105,696 (Table 1), there was no significant effect on lesion size in the mice homozygous for the MCP-1 null alleles (C57E-/-xMCP-1-/-) at any time points tested (Table 3).
|
LTB4 and CCR2 Expression
Because atherosclerosis in C57E-/-xMCP-1-/- mice was not decreased in response to the LTB4 antagonist CP-105,696, it was important to determine that these animals expressed functional LTB4 receptors. Both C57E-/- and C57E-/-xMCP-1-/- mice expressed similar levels of CCR2 and LTB4 receptor mRNA levels in peritoneal macrophages, liver, lung, and spleen, and these levels were unchanged with treatment (data not shown). Reagents were not available to determine receptor protein concentrations. To demonstrate functional LTB4 receptors on macrophages, the chemotactic response to both LTB4 and MCP-1 was measured by using elicited cells. The ability of elicited cells obtained from C57E-/-xMCP-1-/- mice (24±3 cells/x20 field) to migrate in response to LTB4 was identical to cells obtained from C57E-/- mice (25±4 cells/x20 field). The chemotactic response to 10 nmol/L MCP-1 was also similar for cells elicited from either C57E-/-xMCP-1-/- or C57E-/- mice (33±4 versus 27±5 cells/x20 field, respectively).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We investigated the potential role for LTB4 and/or other ligands that bind to the LTB4 receptor in atherosclerosis using inbred strains of LDLr-/- and two strains of apoE-/- mice. We show that in both strains of apoE-/- mice and in LDLr-/- mice, lipid staining and foam cell accumulation were significantly reduced in the aortic valve, sinus, brachiocephalic region, and throughout the entire aortic tree after treatment with a specific LTB4 receptor antagonist. Blockage of the LTB4 receptor was achieved through the use of a very specific LTB4 antagonist, CP-105,696 which has robust potency and kinetics in mice.16,17,23
LTB4, a product of the 5-lipoxygenase pathway, induces a complex cascade of molecular and cellular events including chemotaxis, the promotion of leukocyte adherence to the vascular endothelium, stimulation of superoxide radical formation, and gene expression.10 Monocyte recruitment into the subendothelial space is the hallmark of atherosclerosis and thus chemotactic factors are likely to play a major role in both the initiation and progression of this disease. LTB4 was originally purified from neutrophils and shown to be a major chemotactic factor for neutrophils.24 However, neutrophils are seldom observed in atherosclerotic lesions, and their role is less clear than in other inflammatory states.3 Besides neutrophils, LTB4 and some of its metabolites have also been shown to activate and attract a variety of other cell types found in atherosclerotic tissues including lymphocytes, natural killer cells, and most notably, monocytes. LTB4 is one of the most potent chemoattractants produced in atherosclerotic lesions, and our data suggest that it may be proatherogenic because of its ability to promote the adhesion to, and chemotaxis of, monocytes and leukocytes across the endothelium.
LTB4 produced by 5-lipoxygenase and other eicosanoids that interact with the LTB4 receptor have been implicated in a variety of human inflammatory diseases although their role in atherosclerosis has not been established. Considerable attention has been directed to the role of lipoxygenase and particularly 12- and 15-lipoxygenase in LDL oxidation and subsequent atherosclerosis. Cyros et al25 demonstrated that the absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apoE-deficient mice. Other circumstantial evidence has been provided that suggests lipoxygenases have a pathogenic role in the modification of LDL found in atherosclerotic lesions.26 Others have found that 5- lipoxygenase activity is not essential for human monocyte-mediated LDL oxidation.27
Other LTB4 receptor ligands can be generated by lipid peroxidation occurring in atherosclerotic lesions by a variety of enzymatic and nonenzymatic reactions.28 Harrison and Murphy13 demonstrated that free radical oxidation can lead to the formation of numerous isomers of LTB4, B4 isoleukotrienes, which also activate inflammatory cells by binding to the LTB4 receptor. In addition to neutrophils, LTB4 is a major product of aortic endothelial cells and activated monocytes. Moreover, LTB4 and B4 isoleukotrienes are produced in atherosclerotic lesions, and the levels of LTB4 have been correlated with the degree of leukocyte infiltration in human atherosclerotic plaques.12
Although the source of LTB4 in atherosclerotic lesions is unclear, one measurable effect of antagonizing the LTB4 receptor in our atherosclerotic mice was the reduced surface expression of the ß2 integrin CD11b in both vascular lesions and whole blood. The recruitment of monocytic cells into an area of inflammation is dependent on a set of highly regulated events. This sequence includes the coordinate induction of chemotactic factors as well as adhesion factors known as integrins. The integrin family of adhesion molecules actively participates and is required for cellular recruitment of cells. In addition to inducing chemotaxis through its receptor, LTB4 also stimulates leukocytes through modulation of integrin expression.17,29 The LTB4 antagonist CP-105,696 has been previously shown to inhibit monocyte chemotaxis in vivo and treatment with CP-105,696 significantly decreased macrophage CD11b expression in murine cardiac allograft transplant studies.15 It was unclear, however, if changes in tissue CD11b staining represented changes in monocyte numbers or activation. In the present study, antagonism of LTB4 receptors clearly decreased whole blood monocyte CD11b upregulation in apoE-/- mice without affecting total circulating monocyte numbers. Therefore, it is tempting to speculate that one protective effect of LTB4 antagonism is via modulation of CD11b interaction with its cognate ligands (eg, ICAM-1) which is upregulated in lesion prone sites of apoE-deficient mice.30 Nageh et al31 demonstrated a 50% to 70% reduction in atherosclerotic fatty streaks in mice with homozygous mutations for ICAM-1. Patel et al32 demonstrated antibodies against the ICAM-1 adhesion factor that reduced macrophage recruitment to atherosclerotic plaques in apoE-deficient mice. However, the potential redundancy among the intracellular adhesion ligands makes it difficult to demonstrate cause and effect relationships. For example, Manka et al33 demonstrated that the absence of ICAM-1 does not protect against neointima formation after arterial injury whereas P selectin deficiency is critical for monocyte recruitment in this model. One possibility is that diminished CD11b expression, and thus the potential impairment of migratory and activation events of macrophages, lead to a reduction in lesion development. Kubo et al34 further reported that leukocyte CD11b expression may not be essential for the development of atherosclerosis in mice. Nevertheless, reductions in CD11b expression in the presence of CP-105,696 suggest that the activation state of monocytes is significantly attenuated in atherosclerotic lesions as manifested in whole blood.
In this study, blockade of the LTB4 receptor reduced the monocytic infiltrate in vascular lesions in both chow-fed apoE-/- and fat-fed LDLr-/- mice. The magnitude of this response is comparable to the reduction in lesions observed in mice after MCP-1 gene disruption,35 or the MCP-1 receptor (CCR2).8,9 It is interesting to note that although MCP-1 has a powerful effect on monocyte recruitment, MCP-1-deficient mice still mount a significant tissue macrophage infiltrate,9,31 especially in latter stages of lesion development. Interestingly, we found that blockade of the LTB4 receptor did not eliminate or decrease the residual monocytic infiltrate seen in MCP-1-deficient animals. The absence of any notable effect on lesion size or development may suggest that the anti-atherosclerotic effects of LTB4 antagonism either require MCP-1 or interrupt a pathway common to both MCP-1 and LTB4. Matsukawa et al36 suggested that MCP-1 amplifies the inflammatory response via increasing the production of LTB4. Our results show that LTB4 receptor antagonism with CP-105,696 prevents lesion progression in a preclinical animal model of atherosclerosis and suggests that LTB4 receptor antagonists may have clinical value in the treatment of atherosclerosis in man.
|
Acknowledgments |
|---|
The authors thank Roy Jarvis and Paul McGill for help with the animal husbandry and Drs Omar Francone, Patrica Uelmen Huey, Dominique Brees, and Lee Morehouse for help and insightful comments during the preparation of this manuscript
Received November 20, 2001; accepted December 18, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Gerrity RG. Cellular events in early atherogenesis in swine.In: Tumbleson ME, ed. Swine in Biomedical Research. New York, NY: Plenum Press; 1985: 1497–1509.
2. Gerrity RG. The role of monocytes in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981; 103: 181–190.[Abstract]
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801–809.[CrossRef][Medline] [Order article via Infotrieve]
4. Senior RM, Daughaday CC. Chemotaxis.In: Crystal RG, ed. The Lung. New York, NY: Raven Press; 1991; 131–139.
5. Rollins B. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells. 1991; 3: 517–524.[Medline] [Order article via Infotrieve]
6.
Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991; 88: 5252–5256.
7.
Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins B, Milos P. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19: 1518–1525.
8. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275–281.[CrossRef][Medline] [Order article via Infotrieve]
9. Boring L, Gosling J, Cleary M, Charo I. Decreased lesion formation in CCR2-/- mice reveals a role of chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.[CrossRef][Medline] [Order article via Infotrieve]
10. Ford-Hutchinson A. Leukotriene B4 in inflammation. Crit Rev Immunol. 1990; 10: 1–12.[Medline] [Order article via Infotrieve]
11.
Samuelsson B, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983; 220: 568.
12. De Caterina R, Mazzone A, Giannessi D, Sicari R, Pelosi W, Lazzerini G, Azzara A, Forder R, Carey F, Caruso D, er al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta. 1988; 47: S182–S185.[Medline] [Order article via Infotrieve]
13.
Harrison KA, Murphy RC. Isoleukotrienes are biologically active free radical products of lipid peroxidation. J Biol Chem. 1995; 270: 17273–17276.
14. Yokomizo T, Isumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387: 620–624.[CrossRef][Medline] [Order article via Infotrieve]
15. Weringer EJ, Perry BD, Sawyer PS, Gilman SC, Showell HJ. Antagonizing leukotriene B4 receptors delays cardiac allograft rejection in mice. Transplantation. 1999; 67: 808–815.[CrossRef][Medline] [Order article via Infotrieve]
16.
Griffiths R, Pettipher E, Koch K, Farrell C, Breslow R, Conklyn M, Smith M, Hackman B, Wemberly D, Milici A, et al. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A. 1995; 92: 517–521.
17.
Showell HJ, Pettipher ER, Cheng JB, Breslow R, Conklyn MJ, Farell CA, Hingorani GP, Salter ED, Hackman BC, Wimberly DJ, et al. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696. J Pharm Exp Ther. 1995; 273: 176–184.
18. Showell H, Breslow R, Conklyn M, Hingorani G, Koch K. Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro. Br J Pharmacol. 1996; 117: 1127–1132.[Medline] [Order article via Infotrieve]
19. Rutledge BJ, Rayburn H, Rosenberg R, North RJ, Gladue RP, Corless CL, Rollins BJ. High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens. J Immunol. 1995; 155: 4838–4843.[Abstract]
20.
Nakashima Y, Plump A, Raines E, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994; 14: 133–140.
21.
Bourassa PK, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1996; 93: 10022–10027.
22.
Goulet JL, Byrum RS, Key ML, Nguyen M, Wagoner VA, Koller BH. Genetic factors determine the contribution of leukotrienes to acute inflammatory responses. J Immunol. 2000; 164: 4899–4907.
23.
Showell HJ, Conklyn MJ, Alpert R, Hingorani GP, Wright KF, Smith MA, Stam E, Salter ED, Scampoli DN, Meltzer S, et al. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J Pharm Exp Ther. 1998; 285: 946–954.
24.
Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. J Biol Chem. 1979; 254: 2643–2646.
25.
Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation. 2001; 103: 2277–2282.
26. Harats D, Mulkins MA, Sigal E. A possible role for 15-lipoxygenase in atherosclerosis. Trends Cardiovasc Med. 1995; 5: 29–36.
27. Folcik VA, Cathcart MK. Assessment of 5-lipoxygenase in human monocyte-mediated LDL oxidation. J Lipid Res. 1993; 34: 69–79.[Abstract]
28. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest. 1993; 91: 2572–2579.[Medline] [Order article via Infotrieve]
29. Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol. 1992; 148: 2423–2428.[Abstract]
30.
Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerotic-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998; 18: 842–851.
31.
Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL. Deficiency of inflammatory cel adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1997; 17: 1517–1520.
32.
Patel SS, Thiagarajan R, Willerson JT, Yeh ETH. Inhibition of 
4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in apoE-deficient mice. Circulation. 1998; 97: 75–81.
33.
Manka D, Collins RG, Ley K, Beaudet AL, Sarembock IJ. Circulation. 2001; 103: 1000–1005.
34.
Kubo N, Boisvert WA, Ballantyne CM, Curtiss LK. Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. J Lipid Res. 2000; 41: 1060–1066.
35. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999; 103: 773–778.[Medline] [Order article via Infotrieve]
36.
Matsukawa A, Hogaboam C, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol. 1999; 163: 6148–6154.
This article has been cited by other articles:
 |
|
 |
|
  V. Rudolph and B. A. Freeman Cardiovascular Consequences When Nitric Oxide and Lipid Signaling Converge Circ. Res., September 11, 2009; 105(6): 511 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Steinberg The LDL modification hypothesis of atherogenesis: an update J. Lipid Res., April 1, 2009; 50(Supplement): S376 - S381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sanchez-Galan, A. Gomez-Hernandez, C. Vidal, J. L. Martin-Ventura, L. M. Blanco-Colio, B. Munoz-Garcia, L. Ortega, J. Egido, and J. Tunon Leukotriene B4 enhances the activity of nuclear factor-{kappa}B pathway through BLT1 and BLT2 receptors in atherosclerosis Cardiovasc Res, January 1, 2009; 81(1): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Allayee, A. Baylin, J. Hartiala, H. Wijesuriya, M. Mehrabian, A. J Lusis, and H. Campos Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction Am. J. Clinical Nutrition, October 1, 2008; 88(4): 934 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lefebvre, J-L. Pepin, J-P. Baguet, R. Tamisier, M. Roustit, K. Riedweg, G. Bessard, P. Levy, and F. Stanke-Labesque Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur. Respir. J., July 1, 2008; 32(1): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-F. Wung and B. E. Aouizerat Candidate Genes of the 5-Lipoxygenase Pathway in Acute Coronary Syndrome: A Pilot Study Biol Res Nurs, April 1, 2008; 9(4): 280 - 292. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Maya-Monteiro, P. E. Almeida, H. D'Avila, A. S. Martins, A. P. Rezende, H. Castro-Faria-Neto, and P. T. Bozza Leptin Induces Macrophage Lipid Body Formation by a Phosphatidylinositol 3-Kinase- and Mammalian Target of Rapamycin-dependent Mechanism J. Biol. Chem., January 25, 2008; 283(4): 2203 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, K. Straat, A. Rahbar, M. Wan, C. Soderberg-Naucler, and J. Z. Haeggstrom Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells J. Exp. Med., January 21, 2008; 205(1): 19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacheco, A. Vieira-de-Abreu, R. N. Gomes, G. Barbosa-Lima, L. B. Wermelinger, C. M. Maya-Monteiro, A. R. Silva, M. T. Bozza, H. C. Castro-Faria-Neto, C. Bandeira-Melo, et al. Monocyte Chemoattractant Protein-1/CC Chemokine Ligand 2 Controls Microtubule-Driven Biogenesis and Leukotriene B4-Synthesizing Function of Macrophage Lipid Bodies Elicited by Innate Immune Response J. Immunol., December 15, 2007; 179(12): 8500 - 8508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF]
|
|
|
|
|
|
Y. Kaetsu, Y. Yamamoto, S. Sugihara, T. Matsuura, G. Igawa, K. Matsubara, O. Igawa, C. Shigemasa, and I. Hisatome Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro Cardiovasc Res, October 1, 2007; 76(1): 160 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lattin, D. A. Zidar, K. Schroder, S. Kellie, D. A. Hume, and M. J. Sweet G-protein-coupled receptor expression, function, and signaling in macrophages J. Leukoc. Biol., July 1, 2007; 82(1): 16 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ahluwalia, A. Y. Lin, A. M. Tager, I. E. Pruitt, T. J. T. Anderson, F. Kristo, D. Shen, A. R. Cruz, M. Aikawa, A. D. Luster, et al. Inhibited Aortic Aneurysm Formation in BLT1-Deficient Mice J. Immunol., July 1, 2007; 179(1): 691 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Rao, P. J. Dunford, X. Xue, X. Jiang, K. A. Lundeen, F. Coles, J. P. Riley, K. N. Williams, C. A. Grice, J. P. Edwards, et al. Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Funk Lipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis. Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1204 - 1206. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ghazalpour, X. Wang, A. J. Lusis, and M. Mehrabian Complex Inheritance of the 5-Lipoxygenase Locus Influencing Atherosclerosis in Mice Genetics, June 1, 2006; 173(2): 943 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, A. Gabrielsen, H. E. Agardh, M. Wan, A. Wetterholm, C.-H. Wong, U. Hedin, J. Swedenborg, G. K. Hansson, B. Samuelsson, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability PNAS, May 23, 2006; 103(21): 8161 - 8166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Christmas, K. Tolentino, V. Primo, K. Z. Berry, R. C. Murphy, M. Chen, D. M. Lee, and R. J. Soberman Cytochrome P-450 4F18 Is the Leukotriene B4 {omega}-1/{omega}-2 Hydroxylase in Mouse Polymorphonuclear Leukocytes: IDENTIFICATION AS THE FUNCTIONAL ORTHOLOGUE OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE CYP4F3A IN THE DOWN-REGULATION OF RESPONSES TO LTB4 J. Biol. Chem., March 17, 2006; 281(11): 7189 - 7196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Islam, S. Y. Thomas, C. Hess, B. D. Medoff, T. K. Means, C. Brander, C. M. Lilly, A. M. Tager, and A. D. Luster The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans Blood, January 15, 2006; 107(2): 444 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Back, D.-x. Bu, R. Branstrom, Y. Sheikine, Z.-Q. Yan, and G. K. Hansson Leukotriene B4 signaling through NF-{kappa}B-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia PNAS, November 29, 2005; 102(48): 17501 - 17506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okuno, T. Yokomizo, T. Hori, M. Miyano, and T. Shimizu Leukotriene B4 Receptor and the Function of Its Helix 8 J. Biol. Chem., September 16, 2005; 280(37): 32049 - 32052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Quehenberger Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis J. Lipid Res., August 1, 2005; 46(8): 1582 - 1590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Heller, E. Liu, A. M. Tager, S. Sinha, J. D. Roberts, S. L. Koehn, P. Libby, E. R. Aikawa, J. Q. Chen, P. Huang, et al. Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment Circulation, July 26, 2005; 112(4): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sabirsh, A. Wetterholm, J. Bristulf, H. Leffler, J. Z. Haeggstrom, and C. Owman Fluorescent leukotriene B4: potential applications J. Lipid Res., June 1, 2005; 46(6): 1339 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pettersson, A. Sabirsh, J. Bristulf, K. Kidd-Ljunggren, B. Ljungberg, C. Owman, and U. Karlsson Pro- and anti-inflammatory substances modulate expression of the leukotriene B4 receptor, BLT1, in human monocytes J. Leukoc. Biol., June 1, 2005; 77(6): 1018 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mehrabian and H. Allayee Vascular Cross-Talk: A Conversation Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1748 - 1749. [Full Text] [PDF]
|
|
|
|
|
|
L. Huang, A. Zhao, F. Wong, J. M. Ayala, M. Struthers, F. Ujjainwalla, S. D. Wright, M. S. Springer, J. Evans, and J. Cui Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1783 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Ryu, K. H. Hong, J. H. Maeng, J.-B. Kim, J. Ko, J. Y. Park, K.-U. Lee, M. K. Hong, S. W. Park, Y. H. Kim, et al. Overexpression of Uncoupling Protein 2 in THP1 Monocytes Inhibits {beta}2 Integrin-Mediated Firm Adhesion and Transendothelial Migration Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 864 - 870. [Abstract] [Full Text]
|
|
|
|
|
|
K. Subbarao, V. R. Jala, S. Mathis, J. Suttles, W. Zacharias, J. Ahamed, H. Ali, M. T. Tseng, and B. Haribabu Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 369 - 375. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Dwyer, H. Allayee, K. M. Dwyer, J. Fan, H. Wu, R. Mar, A. J. Lusis, and M. Mehrabian Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis N. Engl. J. Med., January 1, 2004; 350(1): 29 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. C. Ng, C. M. Quinn, J. A. McCrohon, S. Nakhla, W. Jessup, D. J. Handelsman, D. S. Celermajer, and A. K. Death Androgens Up-Regulate Atherosclerosis-Related Genes in Macrophages From Males But Not Females: Molecular Insights Into Gender Differences in Atherosclerosis J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1306 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gregg, F. M. Rauscher, and P. J. Goldschmidt-Clermont Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch Am J Physiol Cell Physiol, October 1, 2003; 285(4): C723 - C734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Friedrich, A. M. Tager, E. Liu, A. Pettersson, C. Owman, L. Munn, A. D. Luster, and R. E. Gerszten Mechanisms of Leukotriene B4-Triggered Monocyte Adhesion Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1761 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. HSIAI, S. K. CHO, P. K. WONG, M. ING, A. SALAZAR, A. SEVANIAN, M. NAVAB, L. L. DEMER, and C.-M. HO Monocyte recruitment to endothelial cells in response to oscillatory shear stress FASEB J, September 1, 2003; 17(12): 1648 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. de Assis, A. R. Silva, L. F. C. Caiado, G. K. Marathe, G. A. Zimmerman, S. M. Prescott, T. M. McIntyre, P. T. Bozza, and H. C. de Castro-Faria-Neto Synergism Between Platelet-Activating Factor-Like Phospholipids and Peroxisome Proliferator-Activated Receptor {gamma} Agonists Generated During Low Density Lipoprotein Oxidation That Induces Lipid Body Formation in Leukocytes J. Immunol., August 15, 2003; 171(4): 2090 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sjostrom, A.-S. Johansson, O. Schroder, H. Qiu, J. Palmblad, and J. Z. Haeggstrom Dominant Expression of the CysLT2 Receptor Accounts for Calcium Signaling by Cysteinyl Leukotrienes in Human Umbilical Vein Endothelial Cells Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): e37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lotzer, R. Spanbroek, M. Hildner, A. Urbach, R. Heller, E. Bretschneider, H. Galczenski, J. F. Evans, and A. J.R. Habenicht Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate 5-Lipoxygenase-Dependent Circuits of Inflammation and Atherogenesis Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): e32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Radmark 5-Lipoxygenase-Derived Leukotrienes: Mediators Also of Atherosclerotic Inflammation Arterioscler Thromb Vasc Biol, June 1, 2003; 23(7): 1140 - 1142. [Full Text] [PDF]
|
|
|
|
|
|
N. van Royen, I. Hoefer, M. Bottinger, J. Hua, S. Grundmann, M. Voskuil, C. Bode, W. Schaper, I. Buschmann, and J.J. Piek Local Monocyte Chemoattractant Protein-1 Therapy Increases Collateral Artery Formation in Apolipoprotein E-Deficient Mice but Induces Systemic Monocytic CD11b Expression, Neointimal Formation, and Plaque Progression Circ. Res., February 7, 2003; 92(2): 218 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Spanbroek, R. Grabner, K. Lotzer, M. Hildner, A. Urbach, K. Ruhling, M. P. W. Moos, B. Kaiser, T. U. Cohnert, T. Wahlers, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis PNAS, February 4, 2003; 100(3): 1238 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fuentes, M. Hernandez, F. J. Fernandez-Aviles, M. S. Crespo, and M. L. Nieto Cooperation Between Secretory Phospholipase A2 and TNF-Receptor Superfamily Signaling: Implications for the Inflammatory Response in Atherogenesis Circ. Res., October 18, 2002; 91(8): 681 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Rosenfeld Leukocyte Recruitment Into Developing Atherosclerotic Lesions: The Complex Interaction Between Multiple Molecules Keeps Getting More Complex Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 361 - 363. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||